Form 4: Vericel Corp Director Lisa Wright Reports Stock Transactions

Director Lisa Wright reports acquisition of common stock and derivative securities due to vesting of restricted stock units and stock options.

Summary

• Lisa Wright, a director of Vericel Corp, filed a Form 4 detailing changes in beneficial ownership.
• On May 1, 2024, Wright acquired 3,200 shares of common stock due to the vesting of Restricted Stock Units (RSUs) granted on May 3, 2023.
• Wright also acquired 8,000 stock options with an exercise price of $47.08, vesting over a 1-year period, and 3,200 RSUs vesting on the earlier of May 1, 2025, or the date of the first Annual Meeting of Stockholders following May 1, 2024.
• Following these transactions, Wright directly owns 9,017 shares of common stock, 8,000 stock options, and 3,200 RSUs.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing indicating standard compensation practices. There's no indication of unusual activity or concern.

Positives

• The vesting of RSUs and stock options indicates a continued alignment of the director's interests with the company's performance.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates standard compensation practices through stock options and restricted stock units.

Comparison to Industry Standards

• Stock option grants and RSU vesting are common compensation practices among publicly traded companies, including biotechnology firms like Vericel.
• Companies such as CRISPR Therapeutics and Beam Therapeutics also utilize stock options and RSUs as part of their executive compensation packages.
• The vesting schedules and exercise prices are generally aligned with industry norms to incentivize long-term performance and retention.

Stakeholder Impact

• The transactions have a minor positive impact on shareholders as they align the director's interests with the company's long-term performance.

Key Dates